By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > BTK inhibitors > Pirtobrutinib > Pirtobrutinib Dosage
BTK inhibitors
https://themeditary.com/dosage-information/pirtobrutinib-dosage-11480.html

Pirtobrutinib Dosage

Drug Detail:Pirtobrutinib (Pirtobrutinib)

Drug Class: BTK inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Mantle Cell Lymphoma

200 mg orally once daily

Length of Therapy: Until disease progression or unacceptable toxicity occurs.

Comments:

  • Swallow tablets whole with water. Do not cut, crush, or chew tablets.
  • This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Use: For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

Renal Dose Adjustments

  • Mild to moderate renal impairment (eGFR 30 mL/min or more): Not recommended
  • Severe renal impairment (eGFR 15 to 29 mL/min): Decrease dose from 200 mg once daily to 100 mg once daily. If the current dose is 100 mg once daily, decrease to 50 mg once daily. If the current dose is 50 mg once daily, discontinue therapy

Liver Dose Adjustments

Data not available

Dose Adjustments

  • Dose Modification for Specified Adverse Reactions:
If grade 3 or higher non-hematologic toxicity, or absolute neutrophil count (ANC) of 0.5 to 1 x 10(9)/L with fever and/or infection, or ANC less than 0.5 x 10(9)/L lasting 7 days or more, or platelet count 25 to 50 x 10(9)/L with bleeding, or less than 25 x 10(9)/L then:

  • First occurrence: Discontinue therapy until recovery to Grade 1 or baseline, then restart at 200 mg once daily (or original dose).
  • Second occurrence: Discontinue therapy until recovery to Grade 1 or baseline, then restart at 100 mg once daily.
  • Third occurrence: Discontinue therapy until recovery to Grade 1 or baseline, then restart at 50 mg once daily.
  • Fourth occurrence: Discontinue therapy.

  • For Grade 4 non-hematologic toxicity: Evaluate the benefit-risk before resuming treatment at the same dose.

  • Concomitant use with Strong CYP450 3A Inhibitors:
  • Avoid use
  • If unavoidable, decrease pirtobrutnib dose by 50 mg.
  • If at a current dose of 50 mg once daily, discontinue pirtobrutnib for the duration of strong CYP3A inhibitor treatment.
  • After discontinuation of strong CYP3A inhibitor for 5 half-lives, restart pirtobrutinib at the prior dose.

  • Concomitant use with CYP450 3A Inducers:
  • Avoid use with moderate or strong inducers
  • If moderate CYP450 3A inducer use is unavoidable:
  • Increase the dose from 200 mg once daily to 300 mg once daily
  • Or increase by 50 mg if starting dose is 50 mg or 100 mg once daily

Precautions

CONTRAINDICATIONS: None

Pediatric statement:
Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Administer with or without food; should not be cut, crushed, or chewed.
  • Swallow tablets whole with water.
  • Should be taken at the same time daily.
  • Monitor complete blood count regularly during treatment with this drug.

Storage requirements:
  • Store at room temperature 20C to 25C (68F to 77F); excursions permitted between 15C and 30C (59F and 86F)

Patient advice:
  • Read the Patient Information Leaflet.
  • Advise patient to report all adverse events, especially fever, shortness of breath, palpitations, weakness, and dizziness.
  • Notify patients of bleeding risk while on this drug.
  • Discuss the potential for second malignancies especially skin cancers and counsel patients on the frequent use of sunscreen.
  • Pregnant women and females of reproductive potential should be counseled on the risk to a fetus.
  • Breastfeeding should be discontinued while on this drug and for one week after the last dose.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by